Skip to main content

Ohio Man Files Lawsuit Filed Over Side-Effects of Onglyza

Ohio Man Files Lawsuit Filed Over Side-Effects of Onglyza

Ohio Man Files Lawsuit Filed Over Side-Effects of Onglyza

Introduction

An Ohio man filed a product liability case against Bristol-Myers Squibb and AstraZeneca in the U.S. District Court for the District of New Jersey, as he suffered coronary artery disease and congestive heart failure due to the alleged use of diabetes drug Onglyza. The plaintiff had been consuming Onglyza and Kombiglyze XR for several years to treat diabetes. In the complaint filed, he stated Onglyza makers purposely hid critical information about saxagliptin in the drug, which caused him serious and permanent heart injuries.

FDA proposed to add a new warning label for Onglyza in 2016, but even as clinical trials indicated potential dangers of Onglyza, the manufacturers released it into the market.

This lawsuit joins a growing number of similar lawsuits filed by individuals nationwide, who developed heart failure or other health risks due to the inadequate warnings. Onglyza lawsuits are consolidated in the U.S. District Court for the Eastern District of Kentucky, MDL Docket No. 2809, under District Judge Karen K. Caldwell, for coordinated pretrial proceedings.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

First Federal Bellwether Trial Set in Strattice Mesh Case

Categories: Hernia Mesh

Lawyers involved in federal Strattice hernia mesh litigation are scheduled to meet with the presiding judge in the U.S. District Court for the District of New Jersey to…

Tepezza Hearing Loss Trial Set for June 2026

Categories: Tepezza

The U.S. District Judge overseeing all federal Tepezza lawsuits has postponed the start of the first bellwether trial by 60 days.

This decision comes as attorneys…

FDA Moves to Restrict Dangerous 7-OH Opioid Products

Categories: Opioids

In a significant move to combat the ongoing opioid crisis, the U.S. Food and Drug Administration (FDA) has recommended a scheduling action under the Controlled Substances Act (CSA) to regulate certain products containing 7-hydroxymitragynine (7-…

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!